Glutamic Acid Decarboxylase (GAD65) Antibody Assay, Spinal Fluid
Use
The GAD65 Antibody Assay is useful for evaluating patients with autoimmune encephalitis, stiff-person syndrome, autoimmune ataxia, autoimmune epilepsy, and other acquired central nervous system disorders affecting gabaminergic neurotransmission. Serum antibodies directed against the 65-kDa isoform of GAD are detected frequently in various autoimmune neurologic disorders.
Special Instructions
This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, due to potential assay interference. Specimens are screened for radioactivity prior to analysis and will be held one week if radioactive, and canceled if radioactivity remains.
Limitations
The clinical utility of this test remains to be determined. Specimen can be rejected due to gross hemolysis, lipemia, or icterus during testing. The test was developed and its performance characteristics are consistent with CLIA requirements; however, it has not been cleared or approved by the FDA.
New York Approved
Methodology
Immunoassay (RIA)
Biomarkers
LOINC Codes
- 94711-9
- 94711-9
Result Turnaround Time
3-6 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1.5 mL
Minimum Volume
1 mL
Container
Sterile vial
Collection Instructions
Submit specimen from collection vial 2.
Patient Preparation
This test should not be requested in patients who have recently received radioisotopes.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |